HRP20201422T1 - Ljudska anti-tau antitijela - Google Patents
Ljudska anti-tau antitijela Download PDFInfo
- Publication number
- HRP20201422T1 HRP20201422T1 HRP20201422TT HRP20201422T HRP20201422T1 HR P20201422 T1 HRP20201422 T1 HR P20201422T1 HR P20201422T T HRP20201422T T HR P20201422TT HR P20201422 T HRP20201422 T HR P20201422T HR P20201422 T1 HRP20201422 T1 HR P20201422T1
- Authority
- HR
- Croatia
- Prior art keywords
- tau
- binding fragment
- antibody
- disease
- seq
- Prior art date
Links
- 239000012634 fragment Substances 0.000 claims 12
- 108091033319 polynucleotide Proteins 0.000 claims 8
- 102000040430 polynucleotide Human genes 0.000 claims 8
- 239000002157 polynucleotide Substances 0.000 claims 8
- 208000034799 Tauopathies Diseases 0.000 claims 5
- 206010012289 Dementia Diseases 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 239000013604 expression vector Substances 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 230000000626 neurodegenerative effect Effects 0.000 claims 4
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 3
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 238000004113 cell culture Methods 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 238000003364 immunohistochemistry Methods 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010059245 Angiopathy Diseases 0.000 claims 1
- 208000011990 Corticobasal Degeneration Diseases 0.000 claims 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 1
- 208000009093 Diffuse Neurofibrillary Tangles with Calcification Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 208000002339 Frontotemporal Lobar Degeneration Diseases 0.000 claims 1
- 206010018341 Gliosis Diseases 0.000 claims 1
- 208000032382 Ischaemic stroke Diseases 0.000 claims 1
- 208000026072 Motor neurone disease Diseases 0.000 claims 1
- 208000005314 Multi-Infarct Dementia Diseases 0.000 claims 1
- 208000001089 Multiple system atrophy Diseases 0.000 claims 1
- 206010068871 Myotonic dystrophy Diseases 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 206010056332 Panencephalitis Diseases 0.000 claims 1
- 208000027089 Parkinsonian disease Diseases 0.000 claims 1
- 206010034010 Parkinsonism Diseases 0.000 claims 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 208000036757 Postencephalitic parkinsonism Diseases 0.000 claims 1
- 208000007930 Type C Niemann-Pick Disease Diseases 0.000 claims 1
- 201000004810 Vascular dementia Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 210000000349 chromosome Anatomy 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000007850 fluorescent dye Substances 0.000 claims 1
- 230000007387 gliosis Effects 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 229910001385 heavy metal Inorganic materials 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 201000008319 inclusion body myositis Diseases 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 210000002682 neurofibrillary tangle Anatomy 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 208000002593 pantothenate kinase-associated neurodegeneration Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 208000000170 postencephalitic Parkinson disease Diseases 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000002739 subcortical effect Effects 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
- A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Radiology & Medical Imaging (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
Claims (12)
1. Monoklonsko anti-tau antitijelo ili njegov tau-vezujući fragment, naznačeno time što:
(a) varijabilna regija teškog lanca (VH) sadrži aminokiselinsku sekvencu navedenu u SEQ ID NO: 48 i
varijabilna regija lakog lanca (VL) sadrži aminokiselinsku sekvencu naveden u SEQ ID NO: 49, ili
(b) VH sadrži aminokiselinsku sekvencu navedenu u SEQ ID NO: 47, a VL sadrži aminokiselinsku sekvencu navedenu u SEQ ID NO: 49.
2. Anti-tau antitijelo ili njegov tau-vezujući fragment prema zahtjevu 1, naznačeno time što je anti-tau antitijelo ili tau-vezujući fragment odabran iz skupine koja sadrži Fab, Fab', F (ab')2, i Fd, i Fv, jednolančani Fv (scFv), i jednolančano antitijelo i Fv (sdFv).
3. Anti-tau antitijelo ili njegov tau-vezujući fragment prema zahtjevu 1 ili 2, naznačeno time što anti-tau antitijelo ili njegov tau-vežući fragment sadrži polietilen glikol ili detektirajuću etiketu odabranu iz skupine koja se sastoji od enzima, radioizotopa, fluorescentnog spoja, kemiluminiscentnog spoja, bioluminescentnog spoja i teškog metala.
4. Farmaceutski pripravak koji sadrži anti-tau antitijelo ili njegov tau-vežući fragment prema bilo kojem od zahtjeva 1-3, i farmaceutski prihvatljiv nosač.
5. Izolirani polinukleotid ili polinukleotidi koji sadrže nukleotidnu sekvencu ili nukleotidne sekvence koji kodiraju anti-tau antitijelo ili njegov tau-vezujući fragment prema zahtjevu 1 ili 2.
6. Polinukleotid ili polinukleotidi prema zahtjevu 5, naznačeni time što sadrže niz sekvenca nukleinskih kiselina naveden u SEQ ID NO: 173 i SEQ ID NO: 174.
7. Ekspresijski vektor ili vektori koji sadrže polinukleotid ili polinukleotide prema zahtjevu 5 ili 6.
8. Izolirana stanica domaćina koja sadrži ekspresijski vektor ili vektore prema zahtjevu 7 ili polinukleotid ili polinukleotide prema zahtjevu 5 ili 6.
9. Postupak za pripremu anti-tau antitijela ili njegovog tau-vezujućeg fragmenta, postupak sadrži:
uzgoj stanice domaćina prema zahtjevu 8 u staničnoj kulturi, i
izoliranje anti-tau antitijela ili njegovog tau-vezujućeg fragmenta iz stanične kulture.
10. Anti-tau antitijelo ili tau-vežući fragment prema bilo kojim od zahtjeva 1-3 ili farmaceutski pripravak prema zahtjevu 4, naznačen time što se upotrebljava u liječenju neurodegenerativne taupatije kod ljudskog subjekta kojem je to potrebno, poželjno gdje je neurodegenerativna taupatija odabrana iz skupine koji se sastoji od Alzheimerove bolesti, kompleksa amiotrofične lateralne skleroze / parldonizam-demencije, demencije argirofilnih zrnaca, amiloidne angiopatije britanskog tipa, cerebralne amiloidne angiopatije, kortikobazalne degeneracije, bolesti Creutzfeldta-Jakoba, pugilističke demencije, difuzne neurofibrilarne zapetljanosti s kalcifikacijom, Downovog sindroma, frontotemporalne demencije, frontotemporalne demencije parkinsonizma povezanog sa kromosomom 17, frontotemporalne lobarne degeneracije, GerstmannStréiussler-Scheinker bolesti, Hallervorden-Spatz bolesti, inkluzijskog miozitisa tijela, atrofije više sustava, miotonske distrofije, Niemann-Pickove bolesti tipa C, ne-gvamske bolesti motornog neurona s neurofibrilarnim zapetljanjima, Pickove bolesti, postencefalitičkog parkinsonizama, prethodne proteinske cerebralne amiloidne angiopatije, progresivne subkortikalne glioze, progresivne supranuklearne paralize, subkutanog sklerozirajućeg panencefalitisa, demencije samo sa zapetljanjima, demencije multi-infarkta i ishemičnog moždanog udara.
11. Anti-tau antitijelo ili tau-vežući fragment prema bilo kojem od zahtjeva 1-3 za uporabu u in vivo dijagnostici tauopatije kod ljudskog pacijenta kojem je to potrebno.
12. In vitro metoda dijagnosticiranja ili praćenja progresije neurodegenerativne taupatije, postupak sadrži:
(a) mjerenje razine patološki modificiranog ili agregiranog tau-a u uzorku dobivenom od ljudskog subjekta s anti-tau antitijelom ili njegovim tau-vezujućim fragmentom prema bilo kojem od zahtjeva 1-3, imunohistokemijom (IHC), i
(b) uspoređivanje razine modificiranog ili agregiranog tau-a s referentnim standardom koji pokazuje razinu patološki modificiranog ili agregiranog tau-a u jednom ili više kontrolnih subjekata,
pri čemu je razlika ili sličnost između nivoa patološki modificiranog ili agregiranog tau-a i norma referentne vrijednosti pokazuje da ljudski subjekt ima neurodegenerativnu taupatiju.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261745410P | 2012-12-21 | 2012-12-21 | |
PCT/US2013/076952 WO2014100600A2 (en) | 2012-12-21 | 2013-12-20 | Human anti-tau antibodies |
EP13818637.4A EP2935326B1 (en) | 2012-12-21 | 2013-12-20 | Human anti-tau antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20201422T1 true HRP20201422T1 (hr) | 2021-02-19 |
Family
ID=49920689
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20201422TT HRP20201422T1 (hr) | 2012-12-21 | 2020-09-07 | Ljudska anti-tau antitijela |
Country Status (26)
Country | Link |
---|---|
US (4) | US9598484B2 (hr) |
EP (2) | EP3792278A3 (hr) |
JP (1) | JP6284548B2 (hr) |
KR (1) | KR102234324B1 (hr) |
CN (2) | CN111205368B (hr) |
AU (1) | AU2013361107B2 (hr) |
BR (1) | BR112015014751A8 (hr) |
CA (1) | CA2896066C (hr) |
CY (1) | CY1123518T1 (hr) |
DK (1) | DK2935326T3 (hr) |
EA (1) | EA035932B1 (hr) |
ES (1) | ES2816700T3 (hr) |
HK (1) | HK1216538A1 (hr) |
HR (1) | HRP20201422T1 (hr) |
HU (1) | HUE051320T2 (hr) |
IL (1) | IL239556B (hr) |
LT (1) | LT2935326T (hr) |
MX (1) | MX2015008024A (hr) |
MY (1) | MY184251A (hr) |
PH (2) | PH12015501420A1 (hr) |
PT (1) | PT2935326T (hr) |
RS (1) | RS60899B1 (hr) |
SG (2) | SG11201504822VA (hr) |
SI (1) | SI2935326T1 (hr) |
WO (1) | WO2014100600A2 (hr) |
ZA (1) | ZA201504898B (hr) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130295021A1 (en) | 2010-10-11 | 2013-11-07 | Feng Chen | Human anti-tau antibodies |
MX359555B (es) | 2012-07-03 | 2018-10-02 | Univ Washington | Anticuerpos para tau. |
SG10201707855YA (en) | 2013-03-13 | 2017-10-30 | Prothena Biosciences Ltd | Tau immunotherapy |
EP3486256A3 (en) * | 2014-06-26 | 2019-08-28 | Janssen Vaccines & Prevention B.V. | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau |
ZA201608812B (en) * | 2014-06-26 | 2019-08-28 | Janssen Vaccines & Prevention Bv | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau |
TWI734975B (zh) | 2014-06-27 | 2021-08-01 | 美商C2N醫療診斷有限責任公司 | 人類化抗-tau抗體 |
DE102014013571A1 (de) * | 2014-09-18 | 2016-03-24 | Aj Roboscreen Gmbh | Monoklonaler Antikörper gegen humanes TAU-Protein |
BR112017010498A2 (pt) * | 2014-11-19 | 2017-12-26 | Axon Neuroscience Se | anticorpos tau humanizados em doença de alzheimer |
WO2016137950A1 (en) * | 2015-02-24 | 2016-09-01 | Rpeptide, Llc | Anti-tau antibodies |
JO3576B1 (ar) * | 2015-02-26 | 2020-07-05 | Lilly Co Eli | أجسام مضادة لـ tau واستخداماتها |
AR104875A1 (es) | 2015-06-05 | 2017-08-23 | Genentech Inc | Anticuerpos anti-tau y métodos de uso |
AU2016289755C1 (en) | 2015-07-06 | 2021-08-19 | UCB Biopharma SRL | Tau-binding antibodies |
WO2017005732A1 (en) | 2015-07-06 | 2017-01-12 | Ucb Biopharma Sprl | Tau-binding antibodies |
US11340225B2 (en) | 2016-03-14 | 2022-05-24 | Biogen International Neuroscience Gmbh | Antibody-dependent cell-mediated phagocytosis assay for reliably measuring uptake of aggregated proteins |
EP3452509A1 (en) * | 2016-05-02 | 2019-03-13 | Prothena Biosciences Limited | Antibodies recognizing tau |
HUE060258T2 (hu) | 2016-05-02 | 2023-02-28 | Prothena Biosciences Ltd | Tau immunterápia |
CU24537B1 (es) | 2016-05-02 | 2021-07-02 | Prothena Biosciences Ltd | Anticuerpos monoclonales que compiten por unirse a tau humano con el anticuerpo 3d6 |
EP3464350A1 (en) | 2016-06-07 | 2019-04-10 | Biogen International Neuroscience GmbH | Methods for treating alzheimer's disease |
EP3487880A1 (en) | 2016-07-25 | 2019-05-29 | Biogen MA Inc. | Anti-hspa5 (grp78) antibodies and uses thereof |
CA3032692A1 (en) | 2016-08-09 | 2018-02-15 | Eli Lilly And Company | Combination antibody therapy for the treatment of neurodegenerative diseases |
PE20201186A1 (es) | 2016-12-07 | 2020-11-03 | Genentech Inc | Anticuerpos antitau y metodos de uso |
TWI789371B (zh) * | 2016-12-07 | 2023-01-11 | 美商建南德克公司 | 抗-tau抗體及使用方法 |
US20200031895A1 (en) | 2016-12-16 | 2020-01-30 | Biogen Ma Inc. | Stabilized proteolytically activated growth differentiation factor 11 |
BR112019017021A2 (pt) | 2017-02-17 | 2020-04-14 | Denali Therapeutics Inc | anticorpos anti-tau e métodos de uso dos mesmos |
JP2018139530A (ja) | 2017-02-27 | 2018-09-13 | 帝人ファーマ株式会社 | 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤 |
SG10202110737WA (en) * | 2017-03-28 | 2021-11-29 | Janssen Vaccines & Prevention Bv | Methods for detection of tau protein aggregation modulating compounds |
MA48996A (fr) | 2017-03-28 | 2020-02-05 | Genentech Inc | Méthodes de traitement de maladies neurodégénératives |
MX2019013045A (es) * | 2017-05-02 | 2020-02-12 | Prothena Biosciences Ltd | Anticuerpos que reconocen tau. |
MX2020003857A (es) | 2017-10-16 | 2021-01-08 | Eisai R&D Man Co Ltd | Anticuerpos anti-tau y uso de los mismos. |
WO2019133799A1 (en) * | 2017-12-29 | 2019-07-04 | University Of Florida Research Foundation | Monoclonal antibodies targeting microtubule-binding domain of tau protein |
CN112105640A (zh) * | 2018-03-05 | 2020-12-18 | 詹森药业有限公司 | 检测神经退行性变的测定 |
CA3090356A1 (en) * | 2018-03-11 | 2019-09-19 | Koorosh Shahpasand | Conformation-independent antibodies against neurotoxic tau proteins |
CN112543648A (zh) | 2018-07-31 | 2021-03-23 | 伊莱利利公司 | 组合疗法 |
BR112021006123A2 (pt) * | 2018-10-19 | 2021-07-20 | Janssen Vaccines & Prevention B.V. | anticorpos anti-sinucleína |
BR112021008105A2 (pt) | 2018-10-29 | 2021-08-03 | Biogen Ma Inc. | variantes de fc5 humanizadas e estabilizadas para intensificação de transporte através de barreira hematoencefálica |
WO2020097561A1 (en) * | 2018-11-08 | 2020-05-14 | Prothena Biosciences Limited | Antibodies recognizing tau |
WO2020252394A2 (en) * | 2019-06-13 | 2020-12-17 | Arizona Board Of Regents On Behalf Of Arizona State University | Targets and methods of diagnosing, monitoring and treating frontotemporal dementia |
GB2600333A (en) * | 2019-07-23 | 2022-04-27 | Univ Shanghai Technology | ASICI channel antagonist antibody |
EP4007773A1 (en) | 2019-08-06 | 2022-06-08 | Aprinoia Therapeutics Limited | Antibodies that bind to pathological tau species and uses thereof |
CN114502480B (zh) * | 2019-10-25 | 2024-04-30 | 东洋纺株式会社 | 能够激光印字的膜及使用了该膜的包装体 |
CN116723856A (zh) | 2020-06-25 | 2023-09-08 | 默沙东有限责任公司 | 靶向丝氨酸413处磷酸化的tau的高亲和力抗体 |
GB202010652D0 (en) * | 2020-07-10 | 2020-08-26 | Wista Lab Ltd | Anti-tau antibodies |
KR20230157296A (ko) * | 2020-12-16 | 2023-11-16 | 보이저 테라퓨틱스, 인크. | 타우 결합 화합물 |
IL310382A (en) | 2021-08-27 | 2024-03-01 | Genentech Inc | Methods for treating tau pathologies |
CA3239708A1 (en) | 2021-12-03 | 2023-06-08 | Aubin MICHALON | Novel potency assay for antibody-based drugs and useful means therefor |
WO2023178049A1 (en) | 2022-03-14 | 2023-09-21 | Genentech, Inc. | Predicting neurodegenerative diseases based on speech analyses |
WO2023250326A1 (en) | 2022-06-21 | 2023-12-28 | Genentech, Inc. | Detecting longitudinal progression of alzheimer's disease (ad) based on speech analyses |
CN117946264B (zh) * | 2024-03-21 | 2024-06-04 | 江西赛基生物技术有限公司 | 一种抗Tau蛋白单克隆抗体及其应用 |
Family Cites Families (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
DE3668186D1 (de) | 1985-04-01 | 1990-02-15 | Celltech Ltd | Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert. |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
ATE243754T1 (de) | 1987-05-21 | 2003-07-15 | Micromet Ag | Multifunktionelle proteine mit vorbestimmter zielsetzung |
US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
WO1989009622A1 (en) | 1988-04-15 | 1989-10-19 | Protein Design Labs, Inc. | Il-2 receptor-specific chimeric antibodies |
EP0428534B1 (en) | 1988-06-14 | 1995-03-29 | Cetus Oncology Corporation | Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
ZA902949B (en) | 1989-05-05 | 1992-02-26 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
DK0463151T3 (da) | 1990-01-12 | 1996-07-01 | Cell Genesys Inc | Frembringelse af xenogene antistoffer |
US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
EP0521985B1 (en) | 1990-03-20 | 1997-09-24 | The Trustees Of Columbia University In The City Of New York | Chimeric antibodies with receptor binding ligands in place of their constant region |
DE69133036T2 (de) | 1990-11-09 | 2003-02-06 | Stephen D. Gillies | Cytokine immunokonjugate |
MX9204374A (es) | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
CA2121599C (en) * | 1991-10-25 | 2007-04-10 | Marc Mercken | Monoclonal antibodies directed against the microtubule-associated protein tau |
JPH07509137A (ja) | 1992-07-24 | 1995-10-12 | セル ジェネシス,インク. | 異種抗体の生産 |
CA2126967A1 (en) | 1992-11-04 | 1994-05-11 | Anna M. Wu | Novel antibody construct |
ES2088838T3 (es) | 1992-11-13 | 2004-01-01 | Idec Pharmaceuticals Corporation | Secuencias kozak de consenso totalmente alteradas destinadas a la expresion en los mamiferos. |
US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
US5843779A (en) | 1992-12-14 | 1998-12-01 | N.V. Innogenetics S.A. | Monoclonal antibodies directed against the microtubule-associated protein tau, and hybridomas secreting these antibodies |
EP0737208B1 (en) | 1993-12-21 | 2006-08-02 | Innogenetics N.V. | Monoclonal antibodies specific for phf-tau, hybridomas secreting them, antigen recognition by these antibodies and their applications |
JPH10506381A (ja) | 1994-07-29 | 1998-06-23 | イノジェネティックス・ナムローゼ・フェンノートシャップ | 特定のサブクラスまたは形態のホスホリレーションされたtauのエピトープに特異的なモノクローナル抗体、それらを分泌するハイブリドーマ、これらの抗体の抗原認識およびそれらの応用 |
EP0822830B1 (en) | 1995-04-27 | 2008-04-02 | Amgen Fremont Inc. | Human anti-IL-8 antibodies, derived from immunized xenomice |
AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
GB9524973D0 (en) | 1995-12-06 | 1996-02-07 | Lynxvale Ltd | Viral vectors |
WO1998022120A1 (en) | 1996-11-19 | 1998-05-28 | The Wistar Institute Of Anatomy & Biology | Diagnostic and therapeutic reagents for alzheimer's disease |
AU737155B2 (en) | 1997-03-14 | 2001-08-09 | Biogen Idec Inc. | Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same |
JP2002512624A (ja) | 1997-05-21 | 2002-04-23 | バイオベーション リミテッド | 非免疫原性タンパク質の製造方法 |
AU1631700A (en) | 1998-11-23 | 2000-06-13 | Idec Pharmaceuticals Corporation | Tumor antigen-specific antibody-gp39 chimeric protein constructs |
US20040110938A1 (en) * | 2000-02-24 | 2004-06-10 | Parekh Rajesh Bhikhu | Proteins, genes and their use for diagnosis and treatment of schizophrenia |
ATE352040T1 (de) | 2000-11-17 | 2007-02-15 | Univ Rochester | In-vitro verfahren zur herstellung und identifizierung von immunglobulin moleküle in eukaryotischen zellen |
PL372140A1 (en) | 2001-01-29 | 2005-07-11 | Idec Pharmaceuticals Corporation | Modified antibodies and methods of use |
US7319139B2 (en) | 2001-01-29 | 2008-01-15 | Biogen Idec, Inc. | TAG-72 specific CH2 domain deleted antibodies |
AT500379B8 (de) | 2001-02-02 | 2009-08-15 | Axon Neuroscience | Tau-proteine |
AU2002355477B2 (en) | 2001-08-03 | 2008-09-25 | Medical Research Council | Method of identifying a consensus sequence for intracellular antibodies |
US20050015819A1 (en) | 2001-08-24 | 2005-01-20 | Jurgen Gotz | Method of inducing the formation of neurofibrillary tangles in transgenic animals |
US20030157641A1 (en) | 2001-11-16 | 2003-08-21 | Idec Pharmaceuticals Corporation | Polycistronic expression of antibodies |
WO2004016655A1 (ja) | 2002-08-14 | 2004-02-26 | Mitsubishi Chemical Corporation | 中枢性タウ蛋白質特異的抗体 |
WO2004095031A1 (en) | 2003-04-24 | 2004-11-04 | Universität Zürich | Method of monitoring immunotherapy |
EP1664116A4 (en) | 2003-08-22 | 2009-06-03 | Biogen Idec Inc | IMPROVED ANTIBODIES WITH CHANGED EFFECTOR FUNCTION AND MANUFACTURING METHOD THEREFOR |
WO2005080986A1 (en) | 2004-02-18 | 2005-09-01 | University Of Iowa Research Foundation | Antibodies to phosphorylated tau, methods of making and methods of use |
JP4730584B2 (ja) | 2004-12-06 | 2011-07-20 | 東亞合成株式会社 | 抗菌ペプチド及びその利用 |
US7083854B1 (en) | 2005-05-10 | 2006-08-01 | Cornell Research Foundation, Inc. | Fibers from polymer nanoclay nanocomposites by electrospinning |
CA2657953A1 (en) | 2005-07-19 | 2007-01-25 | University Of Rochester | Alpha-synuclein antibodies and methods related thereto |
WO2007068105A1 (en) | 2005-12-12 | 2007-06-21 | Robarts Research Institute | Method of diagnosing amyotrophic lateral sclerosis |
US8012936B2 (en) | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
CN101622275B (zh) | 2007-01-05 | 2013-11-06 | 苏黎世大学 | 提供疾患特异性结合分子和靶的方法 |
KR101837329B1 (ko) * | 2008-04-25 | 2018-03-09 | 다이액스 코포레이션 | Fcrn에 대한 항체 및 이들의 용도 |
CN101307108B (zh) * | 2008-06-25 | 2012-04-04 | 南京川博生物技术有限公司 | 抗磷酸化Tau蛋白抗体及其在AD症异常磷酸化Tau蛋白水平测定上的用途 |
US8609097B2 (en) | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
EP4218794A3 (en) * | 2009-06-10 | 2023-09-13 | New York University | Immunological targeting of pathological tau proteins |
WO2011053565A2 (en) | 2009-10-29 | 2011-05-05 | Biomedical Sciences Research Centre "Alexander Fleming" | Compositions and methods for detecting a tauopathy |
PL2625198T3 (pl) * | 2010-10-07 | 2015-12-31 | Ac Immune Sa | Przeciwciała rozpoznające fosfo-tau |
US20130295021A1 (en) * | 2010-10-11 | 2013-11-07 | Feng Chen | Human anti-tau antibodies |
US20120244174A1 (en) * | 2011-01-31 | 2012-09-27 | Intellect Neurosciences Inc. | Treatment of tauopathies |
EP2701743A4 (en) * | 2011-04-27 | 2015-08-19 | Univ Northwestern | SELECTIVE ANTIBODIES FOR TAU PATHOLOGICAL DIMERS AND PRE-FIBRILLARY TAU PATHOLOGICAL OLIGOMERS AND THEIR USE IN THE TREATMENT, DIAGNOSIS AND MONITORING OF TAUOPATHIES |
US20120323214A1 (en) * | 2012-05-16 | 2012-12-20 | Totada R Shantha | Alzheimer's disease treatment with multiple therapeutic agents delivered to the olfactory region through a special delivery catheter and iontophoresis |
-
2013
- 2013-12-20 SG SG11201504822VA patent/SG11201504822VA/en unknown
- 2013-12-20 EP EP20178431.1A patent/EP3792278A3/en not_active Withdrawn
- 2013-12-20 DK DK13818637.4T patent/DK2935326T3/da active
- 2013-12-20 MY MYPI2015001581A patent/MY184251A/en unknown
- 2013-12-20 HU HUE13818637A patent/HUE051320T2/hu unknown
- 2013-12-20 US US14/654,176 patent/US9598484B2/en active Active
- 2013-12-20 EP EP13818637.4A patent/EP2935326B1/en active Active
- 2013-12-20 AU AU2013361107A patent/AU2013361107B2/en not_active Ceased
- 2013-12-20 WO PCT/US2013/076952 patent/WO2014100600A2/en active Application Filing
- 2013-12-20 PT PT138186374T patent/PT2935326T/pt unknown
- 2013-12-20 CN CN201911004609.5A patent/CN111205368B/zh active Active
- 2013-12-20 LT LTEP13818637.4T patent/LT2935326T/lt unknown
- 2013-12-20 EA EA201591020A patent/EA035932B1/ru unknown
- 2013-12-20 KR KR1020157019330A patent/KR102234324B1/ko active IP Right Grant
- 2013-12-20 BR BR112015014751A patent/BR112015014751A8/pt not_active Application Discontinuation
- 2013-12-20 JP JP2015549784A patent/JP6284548B2/ja active Active
- 2013-12-20 SG SG10201705104UA patent/SG10201705104UA/en unknown
- 2013-12-20 MX MX2015008024A patent/MX2015008024A/es active IP Right Grant
- 2013-12-20 ES ES13818637T patent/ES2816700T3/es active Active
- 2013-12-20 CA CA2896066A patent/CA2896066C/en active Active
- 2013-12-20 RS RS20201060A patent/RS60899B1/sr unknown
- 2013-12-20 SI SI201331780T patent/SI2935326T1/sl unknown
- 2013-12-20 CN CN201380073531.7A patent/CN105324394B/zh active Active
-
2015
- 2015-06-19 PH PH12015501420A patent/PH12015501420A1/en unknown
- 2015-06-21 IL IL239556A patent/IL239556B/en active IP Right Grant
- 2015-07-08 ZA ZA201504898A patent/ZA201504898B/en unknown
-
2016
- 2016-04-19 HK HK16104461.4A patent/HK1216538A1/zh unknown
-
2017
- 2017-02-08 US US15/427,843 patent/US20170369560A1/en not_active Abandoned
-
2018
- 2018-06-27 US US16/020,346 patent/US20190169274A1/en not_active Abandoned
-
2019
- 2019-09-24 US US16/580,152 patent/US20200262895A1/en not_active Abandoned
-
2020
- 2020-09-07 HR HRP20201422TT patent/HRP20201422T1/hr unknown
- 2020-09-09 CY CY20201100854T patent/CY1123518T1/el unknown
-
2021
- 2021-01-13 PH PH12021550083A patent/PH12021550083A1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20201422T1 (hr) | Ljudska anti-tau antitijela | |
JP2014503178A5 (hr) | ||
JP2017205118A5 (hr) | ||
IL310464A (en) | Anti-PHF-tau antibodies and uses thereof | |
JP2016029056A5 (hr) | ||
HRP20150831T1 (hr) | Humana anti-alfa- sinuklein auto-protutijela | |
JP2016503065A5 (hr) | ||
HRP20171190T1 (hr) | Protutijelo protiv beta-amiloida i njegove upotrebe | |
JP2016511254A5 (hr) | ||
ES2664576T3 (es) | Un método y un kit para la detección de anticuerpos anti-beta-amiloides | |
JP2015505665A5 (hr) | ||
JP2008533986A5 (hr) | ||
JP2016516997A5 (hr) | ||
JP2015531768A5 (hr) | ||
EP3435085A1 (en) | Composition and kit for diagnosing behavioral addiction, and method of detecting presenilin-1 for diagnosis of behavioral addiction using the same | |
JP2015527365A5 (hr) | ||
JP2017522886A5 (hr) | ||
Chen et al. | Development of an immunochromatographic lateral flow device for rapid diagnosis of Vibrio cholerae O1 serotype Ogawa | |
JP2017502253A5 (hr) | ||
JP2015527368A5 (hr) | ||
Trilling et al. | A broad set of different llama antibodies specific for a 16 kDa heat shock protein of Mycobacterium tuberculosis | |
JP2017526618A5 (hr) | ||
Lascano et al. | Diagnostic tools for immune causes of encephalitis | |
JP2018515071A5 (hr) | ||
Marco | Molecular methods for septicemia diagnosis |